Comparative Pharmacology
Head-to-head clinical analysis: FILKRI versus REVUFORJ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FILKRI versus REVUFORJ.
FILKRI vs REVUFORJ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FILKRI is a sodium–glucose cotransporter 2 (SGLT2) inhibitor. It inhibits SGLT2 in the proximal renal tubule, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels.
REVUFORJ (revumenib) is a potent and selective oral inhibitor of the menin-KMT2A (MLL) protein-protein interaction. It blocks the binding of menin to the N-terminus of KMT2A fusion proteins and mutant NPM1, thereby inhibiting the transcriptional activation of downstream target genes (e.g., HOXA9, MEIS1) that drive leukemogenesis.
Filbanserin 100 mg orally once daily at bedtime.
Oral, 500 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12-16 hours in healthy adults; may be prolonged in hepatic impairment (up to 24 hours) and dose adjustment recommended.
Terminal elimination half-life is approximately 40 hours in healthy subjects; extended to 72 hours in patients with moderate hepatic impairment (Child-Pugh B), requiring dose adjustment.
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; minor metabolism (10-15%) via CYP3A4.
Primarily renal excretion of unchanged drug (approximately 70%) and fecal excretion (approximately 20%) via biliary elimination; minimal metabolism.
Category C
Category C
JAK Inhibitor
JAK Inhibitor